FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

OBJECTIVE: To compare the efficacy, serum drug concentrations, immunogenicity, and safety of FKB327 with the adalimumab reference product (RP) in combination with methotrexate in patients with moderate-to-severe, active rheumatoid arthritis (RA). METHODS: Patients were randomized 1:1 in a double-bli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Genovese, Mark C., Glover, Josephine, Greenwald, Maria, Porawska, Wieslawa, El Khouri, Elias Chalouhi, Dokoupilova, Eva, Vargas, Juan Ignacio, Stanislavchuk, Mykola, Kellner, Herbert, Baranova, Elena, Matsunaga, Nobuhito, Alten, Rieke
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6909638/
https://ncbi.nlm.nih.gov/pubmed/31831079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-019-2046-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados